Valuation: Relay Therapeutics, Inc.

Market Cap 4.3B 3.77B 3.48B 3.25B 6.11B 407B 6.25B 41.85B 16.16B 201B 16.16B 15.8B 697B P/E 2026 *
-12.8x
P/E 2027 * -12.5x
Enterprise Value 4.01B 3.51B 3.24B 3.03B 5.7B 379B 5.83B 39.01B 15.06B 187B 15.06B 14.73B 649B EV / Sales 2026 *
319x
EV / Sales 2027 * 250x
Free-Float
93.62%
Yield 2026 *
-
Yield 2027 * -
1 day+6.36%
1 week+14.24%
Current month+40.50%
1 month+40.50%
3 months+105.62%
6 months+134.72%
Current year+133.33%
1 week 17.54
Extreme 17.54
19.93
1 month 12.92
Extreme 12.925
19.93
Current year 7.01
Extreme 7.01
19.93
1 year 3.02
Extreme 3.025
19.93
3 years 1.78
Extreme 1.775
19.93
5 years 1.78
Extreme 1.775
38.6
10 years 1.78
Extreme 1.775
64.37
Manager TitleAgeSince
Chief Executive Officer 52 2017-02-28
Director of Finance/CFO 49 2018-03-31
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 63 2019-05-31
Director/Board Member 69 2018-10-08
Chairman 54 2015-05-03
Date Insider Type Main position Quantity % Market Cap.
06-21Sell

Chief Financial Officer

-526,055 0.2746%
06-21Fiscal year

Chief Technology Officer

280,368 0.1463%
06-08Free

Director

32,947 0.0172%
Change 5-day change 1-year change 3-year change Capi.($)
+6.36%+14.24%+498.18%+54.22% 4.04B
+0.94%+7.83%-4.77%+3.17% 46.2B
+5.79%+16.17%+421.86%+634.63% 38.71B
+1.12%+15.18%+22.74%-12.71% 31.9B
+3.61%+6.69%+20.23%+62.38% 31.12B
+8.02%+6.35%+17.67%+34.73% 23.77B
+1.13%+15.66% - - 16.2B
+1.45%+17.35%+72.11%+127.60% 15.05B
-1.13%+7.40%+12.03%+20.67% 13.74B
-0.60%+6.32%+102.74%+96.28% 13.42B
Average +2.67%+11.79%+129.20%+113.44% 23.42B
Weighted average by Cap. +2.77%+11.47%+103.37%+141.27%

Financials

2026 *2027 *
Net sales 12.55M 10.99M 10.15M 9.48M 17.84M 1.19B 18.25M 122M 47.14M 586M 47.15M 46.11M 2.03B 16.32M 14.29M 13.19M 12.32M 23.19M 1.54B 23.72M 159M 61.29M 761M 61.3M 59.95M 2.64B
Net income -288M -252M -233M -218M -410M -27.25B -419M -2.8B -1.08B -13.44B -1.08B -1.06B -46.68B -303M -266M -245M -229M -431M -28.69B -441M -2.95B -1.14B -14.15B -1.14B -1.11B -49.14B
Net Debt -292M -256M -236M -220M -415M -27.61B -424M -2.84B -1.1B -13.62B -1.1B -1.07B -47.29B -221M -193M -179M -167M -314M -20.88B -321M -2.15B -829M -10.3B -829M -811M -35.77B
Logo Relay Therapeutics, Inc.
Relay Therapeutics, Inc. is a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease. The Company's Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company's lead clinical asset, zovegalisib (RLY-2608), is the pan-mutant selective PI3Ka inhibitor to enter clinical development and is currently in a Phase 3 clinical trial (ReDiscover-2) in HR+/HER2- metastatic breast cancer. Zovegalisib is also being investigated in a group of genetic disease indications called PI3Ka-driven vascular anomalies. Its pipeline also includes programs for NRAS-driven solid tumors and Fabry disease.
Employees
193
Date Price Change Volume
26-06-29 US$19.74 +6.36% 4,213,257
26-06-26 US$18.56 +4.09% 12,573,933
26-06-25 US$17.83 -1.05% 7,190,474
26-06-24 US$18.02 +3.33% 4,596,966
26-06-23 US$17.44 +0.93% 5,390,191
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
19.74USD
Average target price
24.82USD
Spread / Average Target
+25.73%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RLAY Stock